<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacology of flucytosine (5-FC)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacology of flucytosine (5-FC)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacology of flucytosine (5-FC)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Drew, PharmD, MS, FCCP, FIDP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Perfect, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">Flucytosine</a> (5-fluorocytosine, 5-FC) is an antifungal agent originally developed in 1957 as an antimetabolite. Although it has found no role as an anti-tumor agent, it is used for the treatment of certain fungal infections. Combination therapy of 5-FC with amphotericin B is recommended for the initial management of severe cryptococcal pneumonia and meningoencephalitis and, less frequently, for select invasive candidal infections. Due to a high incidence of primary and/or acquired resistance, use of flucytosine as monotherapy is significantly restricted.</p><p>Hematologic and hepatic toxicities may occur with 5-FC administration but can be reduced by monitoring serum concentrations and by adjusting the dose empirically in patients with renal dysfunction. When serum concentration testing is not available, careful monitoring for cytopenias will be necessary.</p><p>The pharmacology of <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> will be discussed here. The clinical use of flucytosine is discussed separately. (See  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/2443.html" rel="external">"Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2453.html" rel="external">"Candida infections of the central nervous system"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF ACTION</span><span class="headingEndMark"> — </span>5-FC exerts its antifungal effects by interfering with both deoxyribonucleic acid (DNA) and protein synthesis. 5-FC is transported into susceptible fungi by cytosine permease then deaminated to 5-fluorouracil (5-FU) by cytosine deaminase [<a href="#rid1">1</a>]. The absence of cytosine deaminase in mammalian cells allows selective effects on fungal cells [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Following incorporation into DNA, 5-FU is converted to 5-fluorodeoxyuridylic acid monophosphate, which interferes with DNA synthesis [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>5-FC inhibits protein synthesis by a separate mechanism; 5-FU is converted through 5-fluorouridine monophosphate and 5-fluorouridine diphosphate into 5-fluorouridine triphosphate, which is incorporated into fungal ribonucleic acid (RNA), thereby disturbing the amino acid pool and preventing protein synthesis [<a href="#rid2">2</a>].</p><p></p><p>The net result antifungal activity may be static or cidal, depending upon the organism. <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">Flucytosine</a> has demonstrated a prolonged post-antifungal effect (up to four hours) and concentration-independent pharmacodynamic activity [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL USE</span><span class="headingEndMark"> — </span>Combination therapy of 5-FC with amphotericin B is recommended for the initial management of severe cryptococcal pneumonia and meningoencephalitis and, less frequently, for select invasive candidal infections [<a href="#rid5">5,6</a>]. 5-FC is also used as part of an all-oral regimen in combination with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> for cryptococcal meningoencephalitis in countries where it is difficult to give amphotericin B.</p><p>Due to a high incidence of primary and/or acquired resistance, use of <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> as monotherapy is significantly restricted. Monotherapy with 5-FC may be considered in selected cases of chromoblastomycosis/phaeohyphomycosis and genitourinary candidal infections that are not life-threatening and for which treatment alternatives, such as azoles, are not possible.</p><p>The clinical uses of <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> are discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/2443.html" rel="external">"Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV"</a> and  <a class="medical medical_review" href="/d/html/2423.html" rel="external">"Candida endocarditis and suppurative thrombophlebitis"</a> and  <a class="medical medical_review" href="/d/html/2453.html" rel="external">"Candida infections of the central nervous system"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MECHANISMS OF RESISTANCE</span><span class="headingEndMark"> — </span>Resistance to 5-FC can result from primary (intrinsic) or acquired resistance. Intrinsic resistance is due to impaired cellular uptake secondary to a mutation in cytosine permease. Acquired resistance results from defects in 5-FC metabolism through mutations in cytosine deaminase or uracil phosphoribosyl transferase and is thought to be a result of either failure of the organism to metabolize the agent or loss of pyrimidine biosynthesis feedback control [<a href="#rid7">7</a>]. The rate of mutation is frequent enough that a resistant mutant strain could be selected during high-burden infections (≥10<sup>6</sup> colony-forming units).</p><p>In vitro data from clinical isolates do not always accurately reflect the incidence of resistance to 5-FC. As an example, <em>Candida albicans </em>demonstrating heterozygous resistance traits are frequently seen among clinical strains. These isolates demonstrate only slight increases in minimum inhibitory concentrations in vitro. However, under clinical conditions of drug exposure, selection of organisms that are more resistant may lead to treatment failure [<a href="#rid1">1,8</a>].</p><p class="headingAnchor" id="H5"><span class="h1">ANTIMICROBIAL ACTIVITY</span><span class="headingEndMark"> — </span>The Clinical and Laboratory Standards Institute has established methods to standardize in vitro testing against <em>Candida </em>spp [<a href="#rid9">9</a>]. Minimum inhibitory concentration &lt;1 mcg/mL by broth microdilution for most yeasts are considered susceptible, while those &gt;2 mcg/mL are considered resistant.</p><p class="headingAnchor" id="H6"><span class="h2">Cryptococcus neoformans</span><span class="headingEndMark"> — </span>The in vitro activity of <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> against <em>Cryptococcus </em>spp varies significantly among reports. Primary resistance rates have been reported to have ranged from 1 to 25 percent of <em>C. neoformans </em>isolates [<a href="#rid10">10-12</a>]. Non-neoformans strains of <em>Cryptococcus</em> may exhibit higher minimum inhibitory concentrations (MICs) to 5-FC [<a href="#rid13">13</a>].</p><p>The in vitro activity of the combination of 5-FC with amphotericin B against cryptococcal isolates is generally at least additive in 5-FC–susceptible isolates. (See  <a class="medical medical_review" href="/d/html/476.html" rel="external">"Pharmacology of amphotericin B"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Candida</span><span class="headingEndMark"> — </span>Reports of in vitro activity of 5-FC against <em>Candida</em> spp have varied by geographic location and species [<a href="#rid14">14-16</a>]. The reported incidence of resistance of <em>Candida albicans</em> to 5-FC ranges from 4 to 15 percent. Most strains of <em>C. glabrata</em> are susceptible to 5-FC. In one report, over 8800 <em>Candida</em> isolates obtained globally were tested for intrinsic resistance to 5-FC [<a href="#rid15">15</a>]. Overall, 95 percent of the isolates evaluated demonstrated in vitro susceptibility. With the exception of <em>C. krusei</em> (only 5 percent susceptible), resistance among a variety of <em>Candida </em>spp tested was uncommon. A later study that tested the in vitro activity of 5-FC against 254 clinical isolates of <em>C. krusei</em> collected worldwide found a similar rate of susceptibility (8 percent) [<a href="#rid16">16</a>].</p><p>Although infrequent, clonal outbreaks of 5-FC resistance in select <em>Candida</em> spp have been reported. In one such report, 45 (35 percent) of 130 <em>C. tropicalis</em> bloodstream isolates over a four-year period were reported to be 5-FC resistant [<a href="#rid17">17</a>]. The resistant clone was seen more commonly in patients with malignancies, particularly hematologic malignancies.</p><p>When 5-FC is tested in vitro in combination with amphotericin B against <em>Candida </em>spp, an additive effect or synergy was reported in 35 of 40 (85 percent) of isolates [<a href="#rid18">18</a>].</p><p>Since 2016, outbreaks of infection due to multidrug-resistant <em>Candida auris</em> have been reported [<a href="#rid19">19</a>]. In one report that evaluated 15 isolates, 5-FC potentiated most of the alternate antifungal agents (including amphotericin B, various echinocandins, and <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>) in vitro [<a href="#rid19">19</a>]. Others have reported no evidence of synergy or antagonism between 5-FC and other antifungals [<a href="#rid20">20</a>]. </p><p class="headingAnchor" id="H8"><span class="h2">Other fungi</span><span class="headingEndMark"> — </span>5-FC demonstrates activity in vitro against less pathogenic fungi including <em>Rhodotorula</em> spp and <em>Saccharomyces cerevisiae</em> [<a href="#rid21">21,22</a>]. In addition, most organisms responsible for chromoblastomycosis and some dematiaceous fungi (<em>Cladophialophora </em>spp, <em>Phialophora </em>spp) are susceptible to 5-FC in vitro [<a href="#rid2">2</a>].</p><p>The endemic mycoses (<em>Histoplasma</em>, <em>Blastomyces</em>, <em>Coccidioides </em>species), most <em>Aspergillus </em>species, zygomycetes, and most dermatophytes are resistant in vitro to 5-FC.</p><p class="headingAnchor" id="H9"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span>5-FC is available only as an oral capsule in the United States, although an intravenous formulation is available in Europe [<a href="#rid23">23</a>]. Approximately 80 to 90 percent of 5-FC is absorbed following oral administration [<a href="#rid24">24</a>]. Peak serum levels of 30 to 45 mcg/mL occur one to two hours after a single oral dose of 150 mg/kg. Oral absorption of 5-FC may be reduced in patients with advanced acquired immunodeficiency syndrome (AIDS) [<a href="#rid23">23</a>].</p><p>5-FC is widely distributed due in part to a low degree of protein binding (approximately 4 percent) [<a href="#rid7">7</a>]. The volume of distribution ranges from 0.6 to 0.9 L/kg [<a href="#rid7">7</a>]. Favorable penetration into bone, vertebral discs, and peritoneal and synovial fluid has been documented. Drug concentrations achieved in the spleen, heart, liver, kidney, and lung are equal to those found in the serum. 5-FC concentrations in the cerebrospinal fluid are approximately 60 to 80 percent of simultaneous serum concentrations, whereas urine concentrations are generally several-fold higher than simultaneous serum concentrations [<a href="#rid7">7</a>].</p><p>Up to 96 percent of the total dose of 5-FC is eliminated as unchanged drug in the urine, primarily by glomerular filtration [<a href="#rid7">7</a>]. The elimination half-life of 5-FC ranges from three to eight hours (average six hours) in patients with normal renal function but may extend for up to 60 to 250 hours in patients with end-stage kidney disease. Both hemodialysis and peritoneal dialysis remove significant amounts of 5-FC [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H607084289"><span class="h1">PHARMACODYNAMICS</span><span class="headingEndMark"> — </span>Animal studies suggest that lower peak concentrations (between 40 and 60 mcg/mL) can improve safety while achieving (or exceeding) target exposure [<a href="#rid4">4,25</a>]. In an animal model of disseminated candidiasis, optimal efficacy of 5-FC was achieved when drug concentrations exceeded the organism’s minimum inhibitory concentration for more than 40 percent of the dosing interval [<a href="#rid4">4</a>]. However, studies in humans are lacking and findings may vary between pathogen and with use of combination drug therapy. </p><p class="headingAnchor" id="H10"><span class="h1">DOSING</span></p><p class="headingAnchor" id="H1568990230"><span class="h2">Usual dosing in adults and children</span><span class="headingEndMark"> — </span>5-FC should be given orally in four divided doses (25 mg/kg at six-hour intervals) in both adult and pediatric patients. Because of the commercial availability of a 250 mg capsule, individual oral doses are usually rounded to the nearest 250 mg, especially in adults.</p><p>Although the published dose range of 5-FC in adults with normal renal function is 100 to 150 mg/kg per day, we recommend that a total dose of 100 mg/kg per day not be exceeded. There is rarely an indication for doses higher than 100 mg/kg per day and the risk of toxicity is significant.</p><p>Excessive serum concentrations of 5-FC have been reported in children (especially neonates) even with standard dosing of 100 mg/kg per day [<a href="#rid26">26</a>], so careful serum concentration monitoring is particularly important in such patients.</p><p class="headingAnchor" id="H2044626127"><span class="h2">Special populations</span></p><p class="headingAnchor" id="H11"><span class="h3">Renal dysfunction</span><span class="headingEndMark"> — </span>Dose modification is necessary in patients with renal dysfunction. Empiric oral dose adjustments can be based on measured or estimated creatinine clearance [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>&gt;40 mL/minute: 25 mg/kg every 6 hours</p><p class="bulletIndent1"><span class="glyph">●</span>20 to 40 mL/minute: 25 mg/kg every 12 hours</p><p class="bulletIndent1"><span class="glyph">●</span>10 to ≤20 mL/minute: 25 mg/kg every 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;10 mL/minute: 25 mg/kg every 48 hours</p><p></p><p>It is particularly important to monitor the 5-FC serum concentration in patients with renal impairment, as discussed below. (See <a class="local">'Serum concentration monitoring'</a> below.)</p><p class="headingAnchor" id="H867962757"><span class="h3">Renal replacement therapy</span><span class="headingEndMark"> — </span>Patients undergoing intermittent hemodialysis should receive a 5-FC dose of 25 to 50 mg/kg every 48 to 72 hours after hemodialysis. In patients with significant fluid overload, use of ideal body weight (IBW) may reduce the risk of excessive serum concentrations. </p><p>Limited data exist on the removal of 5-FC from the serum from continuous forms of renal replacement therapy. In one case report of a patient receiving 5-FC while undergoing continuous venovenous hemofiltration (CVVH), supratherapeutic 5-FC concentrations were observed despite reducing the dose up to 50 percent beyond the routine dose reduction of 5-FC made for intermittent hemodialysis [<a href="#rid28">28</a>]. Another case report involving administration of 5-FC in a patient undergoing CVVH recommended a dose of 25 mg/kg daily with a low fluid replacement rate [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H253090714"><span class="h3">Hepatic insufficiency</span><span class="headingEndMark"> — </span>Dosing adjustment is not necessary in patients with hepatic insufficiency.</p><p class="headingAnchor" id="H1987972921"><span class="h3">Obesity</span><span class="headingEndMark"> — </span>We use IBW for dosing of 5-FC in obese patients. This is based on a single case report in which pharmacokinetic estimates were closer to published population estimates when IBW was used in a morbidly obese patient [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3507698574"><span class="h3">Pregnancy</span><span class="headingEndMark"> — </span>Because of the in vivo conversion of 5-FC to 5-fluorouracil (5-FU), 5-FC should be avoided during pregnancy if possible. 5-FU is suspected of producing congenital anomalies in humans and 5-FC has been shown to be teratogenic in rats [<a href="#rid31">31</a>]. However, some cases report 5-FC use during pregnancy without complications [<a href="#rid32">32,33</a>]. Data are lacking on optimal dosing of 5-FC during pregnancy. </p><p>It may be necessary to use 5-FC with amphotericin B in some pregnant patients with cryptococcal meningitis, but the potential risks and justification to use this agent during pregnancy should be discussed with the patient and the appropriate consent obtained whenever possible. </p><p class="headingAnchor" id="H2721465985"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The most significant toxicities of 5-FC are hematologic, hepatic, and gastrointestinal. In particular, leukopenia and thrombocytopenia can limit its use.</p><p>Most of the hematologic toxicity associated with 5-FC is thought to result from the in vivo conversion of 5-FC to <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (5-FU) even though studies have correlated bone marrow toxicity more with 5-FC than 5-FU levels [<a href="#rid34">34</a>]. 5-FC may convert to 5-FU spontaneously or under the influence of <em>Escherichia coli</em> in the gut [<a href="#rid35">35</a>]. Although the enzymes responsible for this conversion are thought to be induced by chronic exposure, toxicity most often occurs during the first two weeks of treatment. Renal dysfunction caused by the concomitant administration of nephrotoxic agents, such as amphotericin B, can lead to 5-FC accumulation and further contribute to dose-related toxicity [<a href="#rid36">36</a>].</p><p>Approximately 5 percent of patients develop elevations in serum aminotransferases or alkaline phosphatase, and hepatic necrosis has been reported. As a result, a strong indication must be present to justify administration of 5-FC to patients with severe liver dysfunction. These hematologic and hepatic abnormalities are seen primarily in patients whose peak serum 5-FC concentrations exceed 100 mcg/mL [<a href="#rid37">37</a>]. Gastrointestinal complaints such as nausea, vomiting, and diarrhea occur in up to 6 percent of patients. However, such reactions are less clearly related to serum concentrations.</p><p class="headingAnchor" id="H12"><span class="h1">SERUM CONCENTRATION MONITORING</span><span class="headingEndMark"> — </span>Monitoring of serum 5-FC concentrations is performed in order to reduce the risk of toxicity, particularly hematologic toxicity [<a href="#rid38">38,39</a>]. It is particularly important to monitor the 5-FC concentration in patients with renal dysfunction, since the drug accumulates in this setting, which can lead to toxicity. In a retrospective study that included 53 intensive care unit patients, patients with serum concentrations &gt;100 mg/L were significantly more likely to develop thrombocytopenia and hepatotoxicity than those with lower serum concentrations [<a href="#rid37">37</a>].</p><p>Serum 5-FC concentrations should be measured after approximately three to five doses and should be obtained two hours after a dose has been administered [<a href="#rid40">40</a>]. Serum drug concentrations should be repeated following dose adjustment if renal function worsens or if leukopenia or thrombocytopenia occurs.</p><p>All patients receiving 5-FC should undergo regular monitoring of the complete blood count (CBC). In settings in which serum 5-FC concentrations are not available, CBC monitoring two to three times per week provides an indirect method of screening for excessive dosing. An otherwise unexplained reduction in the neutrophil or platelet count may reflect 5-FC toxicity and either the drug should be stopped or the dose reduced.</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT OF TOXICITIES</span><span class="headingEndMark"> — </span>Dose reductions in patients with preexisting renal dysfunction or in those with excessive serum concentrations may help to reduce hematologic and hepatic toxicities resulting from 5-FC administration. While further dose reductions (resulting in reductions in serum concentrations) may permit the continuation of therapy, it would generally not be advisable to reduce serum concentrations below target. In most clinical scenarios, alternate therapies exist, which facilitate the ability to discontinue therapy in patients for whom toxicity is severe.</p><p class="headingAnchor" id="H15"><span class="h1">DRUG INTERACTIONS AND CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Concomitant aluminum hydroxide or <a class="drug drug_general" data-topicid="9582" href="/d/drug information/9582.html" rel="external">magnesium hydroxide</a> delays absorption of 5-FC. The effect of other drugs that raise gastric pH (such as other antacids, histamine-2 antagonists, or proton pump inhibitors) has not been reported. 5-FC is not known to affect the hepatic cytochrome P450 system [<a href="#rid24">24,41</a>].</p><p>Concomitant administration of agents with toxicities similar to 5-FC should be approached with caution. As an example, patients with AIDS who are treated with 5-FC for cryptococcal meningitis may be receiving other agents with hematologic toxicities, such as <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="8485" href="/d/drug information/8485.html" rel="external">ganciclovir</a>, or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. In addition, drugs known to cause renal dysfunction (such as amphotericin B and <a class="drug drug_general" data-topicid="8476" href="/d/drug information/8476.html" rel="external">foscarnet</a>) may alter the elimination of 5-FC and predispose to toxicities related to excessive 5-FC concentrations.</p><p>Although the product information document states that the antifungal activity of 5-FC can be competitively inhibited by <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> [<a href="#rid37">37</a>], there are no published data to support this.</p><p>5-FC is contraindicated in patients with known complete dihydropyrimidine dehydrogenase enzyme deficiency due to increased risk of severe drug toxicity [<a href="#rid42">42</a>]. </p><p class="headingAnchor" id="H3099668465"><span class="h1">DRUG COST AND AVAILABILITY</span><span class="headingEndMark"> — </span>5-FC availability and costs vary widely. In a survey of 125 countries worldwide, 5-FC was unavailable in 89 (71.2 percent) [<a href="#rid43">43</a>]. Furthermore, in most African and Asian countries, despite the high incidence of cryptococcal diseases, 5-FC is not available despite ongoing advocacy [<a href="#rid44">44-46</a>]. In addition, a wide variability in drug costs for 5-FC exists, ranging from USD $4.60 to $1409 per day.</p><p>In one report, a two-week course was estimated to cost $22,000 in the United States compared with $22 in the United Kingdom, using 2015 US prices [<a href="#rid47">47</a>]. However, the US Food and Drug Administration subsequently approved three generic formulations of 5-FC, which has resulted in significant reductions (up to a 78 percent decrease) in the cost of therapy [<a href="#rid48">48</a>]. </p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> − <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">Flucytosine</a> (5-FC) exerts its antifungal effects by interfering with both DNA and protein synthesis. (See <a class="local">'Mechanisms of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>5-FC (in combination with <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> or a lipid formulation of amphotericin B) is the induction therapy of choice for cryptococcal meningoencephalitis and severe cryptococcal pneumonia. It is used less commonly as part of a combination regimen for select invasive candidal infections. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Due to a high incidence of primary and/or acquired resistance, use of <a class="drug drug_general" data-topicid="8451" href="/d/drug information/8451.html" rel="external">flucytosine</a> as monotherapy is significantly restricted. Select cases of chromoblastomycosis/phaeohyphomycosis and genitourinary candidal infections that are not life threatening and for which treatment alternatives, such as azoles, are not possible may be considered for monotherapy. (See <a class="local">'Clinical use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of resistance</strong> − Resistance to 5-FC is thought to be a result of either failure of the organism to metabolize the agent or loss of pyrimidine biosynthesis feedback control. (See <a class="local">'Mechanisms of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial activity</strong> − 5-FC has activity in vitro against <em>Cryptococcus neoformans</em>, many <em>Candida</em> spp, <em>Rhodotorula</em> spp, <em>Saccharomyces cerevisiae</em>, most of the organisms responsible for chromoblastomycosis, and some dematiaceous fungi. (See <a class="local">'Antimicrobial activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>5-FC is available in the United States only as an oral capsule. Approximately 80 to 90 percent of 5-FC is absorbed following oral administration. (See <a class="local">'Usual dosing in adults and children'</a> above and <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The usual dosing of 5-FC in patients with normal renal function is 25 mg/kg orally every six hours. Because of the commercial availability of a 250 mg capsule, individual oral doses are usually rounded to the nearest 250 mg, especially in adults. (See <a class="local">'Usual dosing in adults and children'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dose modification is necessary in patients with renal dysfunction. (See <a class="local">'Renal dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> − Because of the in vivo conversion of 5-FC to 5-fluorouracil and the possible teratogenicity of both compounds, 5-FC should be avoided during pregnancy if possible. It may be necessary to use 5-FC with amphotericin B in some pregnant patients with cryptococcal meningitis, but the potential risks and justification to use this agent during pregnancy should be discussed with the patient and the appropriate consent obtained whenever possible. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> − The most significant toxicities of 5-FC are hematologic, hepatic, and gastrointestinal. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum concentration monitoring</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum 5-FC concentrations should be monitored to reduce the risk of toxicities, particularly hematologic toxicity. It is particularly important to monitor the 5-FC serum concentration in patients with renal impairment. (See <a class="local">'Serum concentration monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of serum 5-FC concentrations is recommended after three to five days of therapy, when available, and should be obtained two hours after a dose has been administered. In settings in which serum 5-FC concentrations are not available, complete blood count monitoring two to three times per week provides an indirect method of screening for excessive dosing. (See <a class="local">'Serum concentration monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy 1975; 21:113.</a></li><li><a class="nounderline abstract_t">Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46:171.</a></li><li><a class="nounderline abstract_t">Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 2000; 20:1335.</a></li><li><a class="nounderline abstract_t">Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000; 44:938.</a></li><li><a class="nounderline abstract_t">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 Suppl 1:119.</a></li><li><a class="nounderline abstract_t">Charlier C, El Sissy C, Bachelier-Bassi S, et al. Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis. Antimicrob Agents Chemother 2015; 60:662.</a></li><li class="breakAll">Clinical Laboratory Standards Institute. M60-Performance Standards for Antifungal Susceptibility Testing of Yeasts, 2nd Edition. June 29, 2020.</li><li><a class="nounderline abstract_t">Chin CS, Cheong YM, Wong YH. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans. Med J Malaysia 1989; 44:194.</a></li><li><a class="nounderline abstract_t">Shadomy HJ, Wood-Helie S, Shadomy S, et al. Biochemical serogrouping of clinical isolates of Cryptococcus neoformans. Diagn Microbiol Infect Dis 1987; 6:131.</a></li><li><a class="nounderline abstract_t">Franzot SP, Hamdan JS. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 1996; 40:822.</a></li><li><a class="nounderline abstract_t">Bava AJ, Negroni R. [In vitro susceptibility of Cryptococcus strains to 5 antifungal drugs]. Rev Inst Med Trop Sao Paulo 1989; 31:346.</a></li><li><a class="nounderline abstract_t">Pujol C, Pfaller MA, Soll DR. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob Agents Chemother 2004; 48:262.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46:3518.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ, Gibbs DL, et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008; 46:515.</a></li><li><a class="nounderline abstract_t">Desnos-Ollivier M, Bretagne S, Bernède C, et al. Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France. Emerg Infect Dis 2008; 14:557.</a></li><li><a class="nounderline abstract_t">Montgomerie JZ, Edwards JE Jr, Guze LB. Synergism of amphotericin B and 5-fluorocytosine for candida species. J Infect Dis 1975; 132:82.</a></li><li><a class="nounderline abstract_t">O'Brien B, Chaturvedi S, Chaturvedi V. In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Bidaud AL, Botterel F, Chowdhary A, Dannaoui E. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005; 55:312.</a></li><li><a class="nounderline abstract_t">Diekema DJ, Petroelje B, Messer SA, et al. Activities of available and investigational antifungal agents against rhodotorula species. J Clin Microbiol 2005; 43:476.</a></li><li><a class="nounderline abstract_t">Brouwer AE, van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51:1038.</a></li><li><a class="nounderline abstract_t">Daneshmend TK, Warnock DW. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet 1983; 8:17.</a></li><li><a class="nounderline abstract_t">Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15:1003.</a></li><li><a class="nounderline abstract_t">Soltani M, Tobin CM, Bowker KE, et al. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006; 28:574.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf (Accessed on April 12, 2022).</li><li><a class="nounderline abstract_t">Kunka ME, Cady EA, Woo HC, Thompson Bastin ML. Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy. Case Rep Crit Care 2015; 2015:927496.</a></li><li><a class="nounderline abstract_t">Williams KN, Bidell MR, Adamsick ML, et al. Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report. Transpl Infect Dis 2021; 23:e13575.</a></li><li><a class="nounderline abstract_t">Gillum JG, Johnson M, Lavoie S, Venitz J. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 1995; 15:251.</a></li><li class="breakAll">Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 12th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2021.</li><li><a class="nounderline abstract_t">Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998; 77:153.</a></li><li><a class="nounderline abstract_t">Costa ML, Souza JP, Oliveira Neto AF, Pinto E Silva JL. Cryptococcal meningitis in HIV negative pregnant women: case report and review of literature. Rev Inst Med Trop Sao Paulo 2009; 51:289.</a></li><li><a class="nounderline abstract_t">Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987; 83:236.</a></li><li><a class="nounderline abstract_t">Vermes A, Guchelaar HJ, van Kuilenburg AB, Dankert J. 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study. Fundam Clin Pharmacol 2002; 16:39.</a></li><li><a class="nounderline abstract_t">Vermes A, Guchelaar HJ, Dankert J. Prediction of flucytosine-induced thrombocytopenia using creatinine clearance. Chemotherapy 2000; 46:335.</a></li><li><a class="nounderline abstract_t">Vermes A, van Der Sijs H, Guchelaar HJ. Flucytosine: correlation between toxicity and pharmacokinetic parameters. Chemotherapy 2000; 46:86.</a></li><li><a class="nounderline abstract_t">Goodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61:17.</a></li><li><a class="nounderline abstract_t">Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53:24.</a></li><li><a class="nounderline abstract_t">Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 69:1162.</a></li><li><a class="nounderline abstract_t">South Africa. Supreme Court, Cape Provincial Division. Castell v. De Greef. S Afr Law Rep 1994; 1994:408.</a></li><li class="breakAll">US Food and Drug Administration. ANCOBON (flucytosine). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/017001s034lbl.pdf (Accessed on March 17, 2022).</li><li><a class="nounderline abstract_t">Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal therapy and its variable cost. J Antimicrob Chemother 2016; 71:3599.</a></li><li><a class="nounderline abstract_t">Govender NP, Meintjes G, Banoo S. Access to flucytosine for HIV-infected patients with cryptococcal meningitis – an urgent need. S Afr Med J 2014; 104:594.</a></li><li><a class="nounderline abstract_t">Loyse A, Dromer F, Day J, et al. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother 2013; 68:2435.</a></li><li><a class="nounderline abstract_t">Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013; 13:629.</a></li><li><a class="nounderline abstract_t">Merry M, Boulware DR. Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clin Infect Dis 2016; 62:1564.</a></li><li><a class="nounderline abstract_t">Rajasingham R, Boulware DR. New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs. Clin Infect Dis 2019; 69:732.</a></li></ol></div><div id="topicVersionRevision">Topic 472 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1098864" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mode of action of 5-fluorocytosine and mechanisms of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10933638" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11079283" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antifungal pharmacodynamics: review of the literature and clinical applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722494" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9988500" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antifungal drug resistance in pathogenic fungi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26525799" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26525799" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for Candida glabrata Cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2696871" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3545655" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Biochemical serogrouping of clinical isolates of Cryptococcus neoformans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8851624" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2560840" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : [In vitro susceptibility of Cryptococcus strains to 5 antifungal drugs].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693548" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Flucytosine resistance is restricted to a single genetic clade of Candida albicans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384359" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077633" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18394272" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clonal population of flucytosine-resistant Candida tropicalis from blood cultures, Paris, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1097545" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Synergism of amphotericin B and 5-fluorocytosine for candida species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31932367" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31591129" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15695538" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15635020" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Activities of available and investigational antifungal agents against rhodotorula species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17194824" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6301738" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical pharmacokinetics of systemic antifungal drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457631" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085019" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17085019" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26246919" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Flucytosine Pharmacokinetics in a Critically Ill Patient Receiving Continuous Renal Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527677" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno-venous hemofiltration and intermittent hemodialysis: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624273" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7624273" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9653427" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cryptococcal pneumonia complicating pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19893983" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Cryptococcal meningitis in HIV negative pregnant women: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3303926" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903511" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 5-fluorocytosine-related bone-marrow depression and conversion to fluorouracil: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10965099" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prediction of flucytosine-induced thrombocytopenia using creatinine clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10671757" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Flucytosine: correlation between toxicity and pharmacokinetic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999982" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antifungal serum concentration monitoring: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18955533" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antifungal therapeutic drug monitoring: established and emerging indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24379304" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041097" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Castell v. De Greef.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12041097" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Castell v. De Greef.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516477" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Global access to antifungal therapy and its variable cost.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26307779" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Access to flucytosine for HIV-infected patients with cryptococcal meningitis–an urgent need.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23788479" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735626" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27009249" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30698690" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
